Kestra Medical Technologies (NASDAQ:KMTS) Director Sells $97,502.40 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Raymond Cohen sold 3,330 shares of Kestra Medical Technologies stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $29.28, for a total transaction of $97,502.40. Following the completion of the sale, the director directly owned 54,790 shares of the company’s stock, valued at approximately $1,604,251.20. This trade represents a 5.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

NASDAQ KMTS opened at $27.43 on Friday. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -10.27 and a beta of 0.51. Kestra Medical Technologies, Ltd. has a 1-year low of $17.34 and a 1-year high of $30.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. The business’s fifty day moving average price is $25.83 and its 200-day moving average price is $23.02.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%.The firm had revenue of $30.97 million during the quarter. On average, equities analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current year.

Kestra Medical Technologies News Summary

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: BTIG issued a Buy rating on KMTS, adding to the constructive analyst outlook. The stock’s consensus price target is approximately $28.38, while BTIG has reportedly set a higher target of $32.00. Kestra Medical Technologies Gets a Buy from BTIG
• Positive Sentiment: Kestra received a five-star rating on Newsweek’s 2026 list of America’s Greatest Mid-Market Companies. It was the only medical equipment manufacturer among the honorees to receive the top rating, providing reputational support for its ASSURE wearable cardioverter defibrillator and broader cardiac-care platform. Kestra Medical Technologies Earns Five-Star Rating
• Neutral Sentiment: KMTS has been trading above its 50-day and 200-day moving averages and near its 52-week high, indicating strong recent momentum. Still, the consensus target of $28.38 suggests relatively limited upside at current levels. Kestra Medical Technologies Consensus Price Target
• Negative Sentiment: Director Raymond Cohen sold 3,330 shares worth about $97,500, reducing his holdings by 5.73%. The sale was disclosed as being used to cover tax withholding tied to vested equity awards, making it less concerning than a discretionary sale, although it adds to recent insider-selling pressure. Kestra Director Sells Shares
• Negative Sentiment: The company remains unprofitable: its latest quarterly loss missed analyst expectations, and analysts expect a full-year loss. That financial profile could restrain valuation despite improving commercial momentum.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LP lifted its stake in shares of Kestra Medical Technologies by 284.2% during the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after buying an additional 44,839 shares in the last quarter. California State Teachers Retirement System raised its holdings in Kestra Medical Technologies by 39.2% during the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after acquiring an additional 7,844 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Kestra Medical Technologies by 6.6% during the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after acquiring an additional 5,731 shares during the period. Quantinno Capital Management LP purchased a new position in shares of Kestra Medical Technologies in the first quarter valued at about $431,000. Finally, Sei Investments Co. boosted its stake in shares of Kestra Medical Technologies by 22.6% in the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after acquiring an additional 43,753 shares during the period.

Analysts Set New Price Targets

A number of research firms recently issued reports on KMTS. Wall Street Zen downgraded shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Piper Sandler reaffirmed an “overweight” rating on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. JPMorgan Chase & Co. began coverage on shares of Kestra Medical Technologies in a research note on Monday, August 10th. They set an “overweight” rating and a $30.00 price target on the stock. Weiss Ratings raised shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 16th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.38.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies designed to help protect patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, or WCD, which is intended to provide temporary protection for patients who may be at elevated risk of life-threatening ventricular arrhythmias.

The ASSURE system continuously monitors a patient’s heart rhythm and is designed to detect potentially dangerous arrhythmias, including ventricular tachycardia and ventricular fibrillation.